The BTX 1503 Phase 2 clinical trial has been designedto deliver data that allows Botanix to explore potential licensing and other corporate opportunities uponsuccessful completion of the study around mid-2019. Plenty of time here.....
Ann: Annual Report to shareholders, page-9
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
-0.008(2.11%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 34.0¢ | $770.7K | 2.205M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 104574 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 311876 | 19 |
View Market Depth
| Last trade - 15.16pm 27/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
